Skip to content
Divis Laboratories logo

Divis Laboratories

DIVISLAB NSE
₹11,180.50 +2.50 (+0.02%)
Market Cap
₹2,96,807 Cr
P/E
88.26
View as Markdown
MCP
Close 20 Nov 2026 ₹11,180.50 1Y +4,821.50 +75.8%
Start ₹6,359.00

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
22.00%
Debt to Equity
0.00
EPS (TTM)
₹126.68
Book Value
₹677.93
Market Cap
₹2,96,807 Cr
P/E (TTM)
88.26
P/B
16.49
ROE
16.50%
Dividend Yield
0.27%
EBITDA
₹3,948 Cr
52W High
₹11,824.00
52W Low
₹5,647.50
Day Range
₹11,025.00 – ₹11,198.00
Volume
4,04,825

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Divis Laboratories peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
Divis Laboratories (this company)
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Median 7 companies1,884.9041.441,23,9805.070.57%16.50%17.80%28,1392,855

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

Category scores

Quality
53
Average
Returns, margins, earnings quality 22% weight
Valuation
24
Poor
Cheap vs sector & own history 24% weight
Growth
67
Strong
Sales & profit trajectory 9% weight
Financial Health
86
Strong
Solvency, leverage, coverage 9% weight
Momentum
92
Strong
Trend strength, vol-adjusted 12% weight
Ownership
48
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.0%

Weaknesses

2
  • Stock is trading at 16.5 times its book value
  • The company has delivered a poor sales growth of 8.67% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1513
OscillatorsBullish054
Moving AveragesStrong Bullish109

Key readings

RSI (14)
67.80
Neutral
MACD (12,26,9)
488.33
Bullish
SMA (50)
9,808.49
Bullish
SMA (200)
7,660.39
Bullish

As of

Analyst Rating

Based on 26 analysts
BUY54%

14 of 26 analysts rate Buy, 5 Hold, 7 Sell.

As of

BUY
14
54%
HOLD
5
19%
SELL
7
27%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+10.83%
5Y+8.67%
3Y+10.78%
1Y+12.82%
TTM+21.56%

Net profit

Net profit growth by window
10Y+8.59%
5Y+5.30%
3Y+12.10%
1Y+17.21%
TTM+35.33%

Operating cash flow

Operating cash flow growth by window
10Y+10.19%
5Y+7.06%
3Y+3.63%
1Y+65.64%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−5.10 pp
5Y−8.55 pp
3Y+2.08 pp
1Y+0.83 pp
TTM+5.73 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹4,064 Cr
Mar 2018₹3,891 Cr
Mar 2019₹4,946 Cr
Mar 2020₹5,394 Cr
Mar 2021₹6,969 Cr
Mar 2022₹8,960 Cr
Mar 2023₹7,768 Cr
Mar 2024₹7,845 Cr
Mar 2025₹9,360 Cr
Mar 2026₹10,560 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1,060 Cr
Mar 2018₹877 Cr
Mar 2019₹1,353 Cr
Mar 2020₹1,377 Cr
Mar 2021₹1,984 Cr
Mar 2022₹2,960 Cr
Mar 2023₹1,823 Cr
Mar 2024₹1,600 Cr
Mar 2025₹2,191 Cr
Mar 2026₹2,568 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,117 Cr −32.7% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 16 Nov 2026
AI opinion · based on fundamentals
Risk high

Divis Laboratories trades at ₹11,080 as of 2026-11-16 with a market cap of ₹2,94,139 crore. The company is virtually debt-free with a debt-to-equity ratio of 0 and has delivered a TTM sales growth of 22% and TTM profit growth of 38%, though the stock commands a premium valuation at a PE of 87.46x and a price-to-book of 16.34x.

Bull Case 8
  • The company is completely debt-free with a debt-to-equity ratio of 0, providing strong financial flexibility and resilience across business cycles.
  • TTM profit growth stands at 38%, a sharp acceleration compared to the 5-year compounded profit growth of 6% and 3-year CAGR of 13%, indicating a meaningful earnings recovery.
  • TTM revenue growth of 22% is well above the 5-year compounded sales CAGR of 9% and the 10-year CAGR of 11%, suggesting improving demand momentum.
  • The stock has delivered a 1-year return CAGR of 76%, rising from a 52-week low of ₹5,647.50 to ₹11,080, reflecting strong market confidence in the business turnaround.
  • 10-year average ROE of 18% and last year's ROE of 17% demonstrate consistently healthy capital efficiency for a debt-free company.
  • The company maintains a healthy dividend payout ratio of 39.0%, returning a meaningful share of profits to shareholders even while reinvesting for growth.
  • ROCE stands at 18.96%, which is attractive for a zero-debt business and indicates efficient deployment of total capital employed.
  • Long-term compounded sales growth of 11% over 10 years and a 10-year stock CAGR of 26% reflect a durable franchise with sustained wealth creation.
Bear Case 5
  • The trailing PE of 87.46x is extremely elevated, implying the market is pricing in substantial future earnings growth that may already be reflected in the stock price.
  • Five-year compounded sales growth of only 9% and compounded profit growth of just 6% over the same period suggest the recent TTM acceleration may not be sustainable over longer horizons.
  • Dividend yield is a mere 0.26%, offering negligible income return to shareholders at the current price of ₹11,080.
  • ROE of 15.32% on a trailing basis has dipped below the 10-year average of 18%, indicating some compression in return on equity despite the debt-free balance sheet.
  • The 5-year stock CAGR of 18% lags the 3-year CAGR of 48% and 1-year CAGR of 76%, suggesting much of the recent re-rating is concentrated in a short window and may be vulnerable to mean reversion.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago

TL;DR: Limited recent news flow for Divis Laboratories. The only notable event is a sizable block trade worth ₹194.80 crore on Oct 22, which by itself is neither bullish nor bearish without knowing the counterparties or motive. With no fresh headwinds or positive catalysts in the latest cycle, the near-term outlook hinges on upcoming quarterly results and broader pharma sector sentiment.

Quarterly Results

₹ Cr
DIVISLAB quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,909
1,855
2,303
2,118
2,338
2,319
2,585
2,410
2,715
2,604
2,831
3,080
3,676
Expenses
1,430
1,366
1,572
1,496
1,622
1,576
1,699
1,681
1,827
1,714
1,897
1,825
2,110
Operating Profit
479
489
731
622
716
743
886
729
888
890
934
1,255
1,566
OPM %
25%
26%
32%
29%
31%
32%
34%
30%
33%
34%
33%
41%
43%
Other Income
86
95
79
79
106
82
86
119
145
14
155
64
94
Interest
1
0
2
0
1
0
1
3
8
6
6
6
13
Depreciation
95
95
95
97
99
99
107
112
113
118
120
133
142
PBT
469
489
713
604
722
726
864
733
912
780
963
1,180
1,505
Tax %
26%
27%
25%
29%
29%
19%
23%
26%
24%
25%
22%
24%
25%
Net Profit
348
358
538
430
510
589
662
545
689
583
751
902
1,127
EPS (₹)
13.11
13.49
20.27
16.20
19.21
22.19
24.94
20.53
25.95
21.96
28.29
33.98
42.45
YoY Sales growth
3
9
18
19
22
25
12
14
16
12
10
28
35

Profit & Loss

₹ Cr
DIVISLAB profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,115
3,776
4,064
3,891
4,946
5,394
6,969
8,960
7,768
7,845
9,360
10,560
12,191
Expenses
1,942
2,354
2,615
2,622
3,072
3,568
4,102
5,075
5,397
5,635
6,387
7,118
7,546
Operating Profit
1,173
1,423
1,450
1,269
1,874
1,826
2,867
3,885
2,370
2,210
2,973
3,442
4,645
OPM %
38%
38%
36%
33%
38%
34%
41%
43%
31%
28%
32%
33%
38%
Other Income
38
93
72
107
154
186
57
112
344
335
348
507
327
Interest
3
5
3
1.33
5
6.1
0.87
2
2
3
2
23
31
Depreciation
136
118
123
142
169
186
256
312
343
378
402
463
513
Exceptional Items
—
—
—
—
—
—
—
—
—
—
—
−74
—
PBT
1,072
1,393
1,395
1,231
1,855
1,819
2,666
3,684
2,369
2,163
2,916
3,388
4,428
Tax %
21%
19%
24%
29%
27%
24%
26%
20%
23%
26%
25%
24%
—
Net Profit
852
1,126
1,060
877
1,353
1,377
1,984
2,960
1,823
1,600
2,191
2,568
3,363
EPS (₹)
32.07
42.41
39.95
33.04
50.96
51.85
74.75
111.52
68.69
60.27
82.53
96.73
126.68
Div. Payout %
31%
24%
25%
30%
31%
31%
27%
27%
44%
50%
36%
31%
—
Sales growth
23
21
8
−4
27
9
29
29
−13
1
19
13
22

Balance Sheet

₹ Cr
DIVISLAB balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
27
53
53
53
53
53
53
53
53
53
53
53
53
Reserves
3,469
4,240
5,304
5,872
6,904
7,257
9,242
11,675
12,714
13,518
14,916
16,708
17,944
Borrowings
27
42
36
63
106
39
5
4
3
3
4
7
6
Other Liabilities
883
562
762
797
973
1,183
1,471
1,628
1,654
1,886
1,948
3,251
3,961
Total Liabilities
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
21,964
Fixed Assets
1,309
1,439
1,559
1,996
2,088
2,782
3,704
4,325
4,723
4,739
5,442
6,528
7,473
CWIP
218
264
444
120
492
920
711
470
212
778
1,022
2,113
1,638
Investments
733
803
1,631
1,889
1,946
971
0
72
77
82
65
69
71
Other Assets
2,145
2,392
2,521
2,780
3,511
3,858
6,356
8,493
9,413
9,861
10,392
11,309
12,782
Total Assets
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
21,964

Cash Flow

₹ Cr
DIVISLAB cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
826
1,038
1,150
776
954
1,216
1,947
1,912
2,460
1,261
1,653
2,738
Investing
−521
−406
−1,140
−478
−685
−83
75
−2,195
−2,708
−269
−804
−2,219
Financing
−303
−631
2
−314
−246
−1,091
−35
−532
−797
−799
−799
−804
Net Cash Flow
3
0
13
−17
23
41
1,987
−816
−1,045
193
50
−285
Free Cash Flow
519
642
774
502
221
33
1,037
1,199
1,987
258
215
221
CFO/EBITDA
88
91
100
82
77
91
90
66
124
74
83
105

Ratios

DIVISLAB financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
85
81
95
86
96
88
99
84
100
106
103
Inventory Days
350
293
307
314
347
316
329
341
352
364
311
346
Days Payable
68
56
104
96
96
100
117
96
89
94
88
106
Cash Conversion Cycle
368
322
284
313
336
312
300
344
347
370
330
343
Working Capital Days
140
158
147
176
169
180
152
177
188
206
192
195
ROCE %
33%
36%
29%
22%
29%
25%
32%
35%
19%
16%
20%
22%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Divis Laboratories insights

72 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.88%
  • FIIs 20.38%
  • DIIs 19.17%
  • Public 6.55%
  • Others 2.03%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Divis Laboratories

What does Divis Laboratories Ltd do?
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients
Where is Divis Laboratories Ltd (DIVISLAB) listed?
Divis Laboratories Ltd trades as DIVISLAB on the NSE and under code 532488 on the BSE.
Which sector does Divis Laboratories Ltd belong to?
Divis Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Divis Laboratories Ltd?
Divis Laboratories Ltd has a market capitalisation of ₹2,96,807 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Divis Laboratories Ltd?
Divis Laboratories Ltd trades at a PE ratio of 88.26 as of 20 Nov 2026, on earnings per share of ₹126.68, against a book value of ₹677.93 per share.
What is the 52-week high and low of Divis Laboratories Ltd?
Over the last 52 weeks Divis Laboratories Ltd has traded between ₹5,647.5 and ₹11,824 as of 20 Nov 2026.
Does Divis Laboratories Ltd pay dividends?
Divis Laboratories Ltd has a dividend yield of 0.27%.
What is the Return on Equity (ROE) of Divis Laboratories Ltd?
Divis Laboratories Ltd reported a return on equity of 16.50%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients

CEO Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Employees 10,542
Listed 12 Mar 2003
Face Value ₹2
Shares Outstanding 26,54,68,580

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DIVISLAB.md for Divis Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More